The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Agomab Therapeutics’ AGMB-447, an inhaled small molecule ALK5-inhibitor, for treating idiopathic pulmonary fibrosis (IPF).
GlaxoSmithKline (GSK) has acquired all outstanding shares of Canadian biopharmaceutical firm Bellus Health for a total equity price of $2bn or $14.75 for each share in cash.
China National Medical Products Administration has accepted the review of GSK’s drug application for Nucala (mepolizumab) as an add-on maintenance treatment for severe eosinophilic asthma (SEA).
ReCode Therapeutics has announced that it will secure a strategic investment from the Cystic Fibrosis Foundation (CF Foundation) to develop its inhaled mRNA-based therapeutic for cystic fibrosis (CF).
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has given approval to Beyfortus (nirsevimab) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.
AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency as an add-on therapy in patients aged 12 years and above suffering with severe asthma.
China-based biotech company Therorna has secured $42m in a Series A financing round to support its growth and fuel product pipeline development.
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Boehringer Ingelheim’s new oral therapy, BI 1015550, to treat patients with idiopathic pulmonary fibrosis (IPF).
Pfizer has signed an agreement to deliver an additional 2.5 million treatment courses of its investigational Covid-19 pill Paxlovid to the UK.
Merck and Ridgeback Biotherapeutics have initiated a Phase III clinical trial to evaluate investigational oral antiviral therapeutic molnupiravir to prevent Covid-19 infection.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.